To date, all population-based epidemiologic data on gastrointestinal stromal tumor (GIST) in the United States predate the 2001 implementation of GIST-specific histology coding. As such, results from previous studies were limited because of inclusion of non-GIST abdominal or gastrointestinal sarcomas. We used a national cancer registry with modern day histologic codes to gain greater insight into the true epidemiology of GIST in the United States. We identified 6,142 patients diagnosed with GIST between 2001 and 2011 in the Surveillance, Epidemiology, and End Results database. Incidence, survival, demographic risk factors, and prognostic factors were analyzed. Annual age-adjusted incidence rose from 0.55/100,000 in 2001 to 0.78/100,000 in 2011 and increased with age, peaking among 70-to 79-year-olds (3.06/ 100,000). GIST was also more common in males than females [rate ratio (RR), 1.35], non-Hispanics than Hispanics (RR, 1.23), and blacks (RR, 2.07) or Asians/Pacific Islanders (RR, 1.50) than whites. The study period had 5-year overall and GIST-specific survival rates of 65% and 79%, respectively. The 5-year overall survival rates for those with localized, regional, and metastatic disease at diagnosis were 77%, 64%, and 41%, respectively. Multivariate analyses demonstrated that older age at diagnosis, male sex, black race, and advanced stage at diagnosis were independent risk factors for worse overall survival. Multivariate analysis also showed the four aforementioned characteristics, along with earlier year of diagnosis, to be independent risk factors for worse GIST-specific survival. As the first population-based, epidemiologic study of histologically confirmed disease, our findings provide a robust representation of GIST in the era of immunohistochemical diagnoses. Cancer Epidemiol Biomarkers Prev; 24(1); 298-302. Ó2014 AACR.
Introduction
Gastrointestinal stromal tumor (GIST) represents the most common sarcoma of the gastrointestinal (GI) tract. However, until the late 1990s, it was often confused with submucosal and abdominal tumors (1) , including leiomyoma and leiomyosarcoma, as well as S100-positive spindle cell tumor, myofibroblastic tumor, desmoid, and KIT-positive metastatic melanoma (2, 3) . The lack of uniform nomenclature and histologic distinction resulted in frequent misdiagnoses by pathologists, as well as miscoding by cancer registrars (3) . Therefore, before the implementation of a GIST-specific histology code in 2001, populationbased studies were frequently limited because of the inclusion of non-GIST abdominal and GI sarcomas (1, (4) (5) (6) (7) . In turn, this reduced the accuracy of older GIST epidemiology research. This began to change in 1998, when Hirota and colleagues reported that GIST was initiated by gain-of-function mutations in KIT (c-KIT, CD117) with associated KIT-positive immunostaining (8) , thereby providing a more objective basis upon which to identify and diagnose GIST. The purpose of this study is to define the epidemiology of GIST in the modern era of precise pathologic diagnoses.
Materials and Methods
Using the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database (9), we identified 6,142 patients diagnosed with histologically confirmed GIST between 2001 and 2011 using GI tumor site codes (C150-C189, C199, C209-C212, C218, C220-C221, C239-C260, C268-C269, C480-C482, C488) and the GIST-specific histology code (ICD-O-3 code 8936). Follow-up extended through December 2011, at which point 4,170 patients were alive. Age-adjusted incidence rates per 100,000 subjects were calculated on the basis of 5-year age categories as calculated by SEER-Stat software. The 2000 U.S. standard population was used as the denominator in generating these age-adjusted rates (10) . Ninety-five percent confidence intervals (95% CI) for incidence rates were determined with the Tiwari method (11). Overall survival was determined using Kaplan-Meier curves, and GIST-specific survival was determined using cumulative incidence analyses. Risk factors for overall survival were assessed with a multivariate Cox regression, and risk factors for GIST-specific survival were assessed with a FineGray regression. Multivariate analysis included age as a continuous variable, sex, race, ethnicity, tumor site and size, disease stage at diagnosis (SEER historic stage), and year of diagnosis. Sixteen percent of patients had missing tumor sizes, and these were categorized into a "missing" group for analysis. Associations were considered statistically significant if the 95% confidence interval excluded the null value. Incidence rates were calculated with SEER-Stat (version 8.1.5), and survival analyses were conducted with SAS (version 9.4). Table 1 shows incidence rates stratified by demographic and GIST-specific factors. The annual incidence rate for the entire study period was 0.68 per 100,000 (95% CI, 0.66-0.69 per 100,000) and increased steadily over the study period, from 0.55 per 100,000 (95% CI, 0.50-0.61 per 100,000) in 2001 to 0.78 per 100,000 (95% CI, 0.72-0.84 per 100,000) in 2011. Annual incidence also increased with age, from 0.01 per 100,000 (95% CI, 0.01-0.02/100,000) for those under age 20 years to 2.72 per 100,000 (95% CI, 2.53-2.91 per 100,000) for those above age 80 years, with a peak of 3.06 per 100,000 (95% CI, 2.91-3.23/ 100,000) for those between 70 and 79 years of age. The median age at diagnosis was 64 years, and the range extended between 8 and 101 years. GIST was 36% more common in men than women [rate ratio (RR), 1.35] , and 23% more common in non-Hispanics than Hispanics (RR, 1.23). In addition, blacks and Asians/Pacific Islanders were 2.07 and 1.50-times more likely to develop GIST than whites, respectively. The most common tumor sites were the stomach (55%) and small intestine (29%); the remaining 16% was comprised of all other sites. Kaplan-Meier curves are shown in Fig. 1 , both for the entire study period and for patients stratified by disease stage. For all GIST patients, the 5-year cancer-specific survival rate was 79% (95% CI, 77%-80%), and the 5-year overall survival rate was 65% (95% CI, 64%-67%; Fig. 1A ). Of the 3,336 patients with localized disease at diagnosis, the 5-year overall survival rate was 77% (95% CI, 75%-78%), and of the 895 patients with regional disease at diagnosis, the 5-year overall survival rate was 64% (95% CI, 60%-67%). These were superior to the 5-year overall survival rate of 41% (95% CI, 38%-44%) among the 1,346 patients with metastatic disease at diagnosis (Fig. 1B) .
Results
Risk factors for overall and GIST-specific survival are shown in Table 2 . After controlling for sex, age at diagnosis, race and ethnicity, tumor site and size, disease stage, and year of diagnosis, we found the following factors to be independently associated with worse overall survival: increased age at diagnosis [hazard ratio (HR), 1.58], male sex (HR, 1.41), black race (HR, 1.26), and regional (HR, 1.59), or metastatic (HR, 2.81) disease at diagnosis. Hispanic versus non-Hispanic ethnicity, tumors in the stomach versus the small intestine, primary tumors greater than 5 cm versus smaller than 2 cm, and earlier versus later diagnostic years did not seem to be independently associated with worse overall survival.
Like overall survival, increased age at diagnosis (HR, 1.27), male sex (HR, 1.36), black race (HR, 1.24), and regional (HR, 1.66) or metastatic (HR, 3.11) disease at diagnosis were statistically significantly associated with worse GIST-specific survival on multivariate analysis. However, Hispanic versus non-Hispanic ethnicity, tumors in the stomach versus the small intestine, and primary tumors greater than 5 cm versus smaller than 2 cm were not statistically significantly associated with GIST-specific mortality.
Discussion
Our study represents the first population-based assessment of GIST epidemiology in the United States using ICD-O-3 coding. Whereas some of our results supported previous studies, others differed from earlier findings, providing a comprehensive description and statistical examination of GIST in the modern era of immunohistochemical diagnoses. We examined incidence trends by demographic and tumor-specific characteristics, determined survival trends, and found several risk factors to be independent predictors of mortality.
Among the patients in our study period, age-adjusted incidence rose 42% over a decade, from 0.55 per 100,000 in 2001 to 0.78 per 100,000 in 2011. A previous study with older SEER data found a 25-fold increase in disease incidence from 1992 to 2002 (e.g., 0.03 per 100,000 to 0.69 per 100,000; ref. 1), although the considerable increase was likely attributable to the prevalent reclassification of misdiagnosed smooth muscle tumors as GIST during the latter years. Two additional studies reported average GIST incidences of 0.32 per 100,000 between 1993 and 2002 (7) and 0.68 per 100,000 between 1992 and 2000 (4), but these results were likely limited by aforementioned pathologic and coding issues. Therefore, though the overall incidence in our study (0.68 per 100,000) was similar to the one reported in a previous SEERbased report (4), our findings more accurately reflect the presentday incidence of GIST in the United States.
We found GIST to be more common in males, non-Hispanics, blacks, and Asians/Pacific Islanders. As such, our analyses confirmed results of several previous population-based studies that found increased incidence among males (4, 6, 12) , as well as one study reporting that GIST incidence in blacks was approximately twice the incidence in whites (4). We also found increased incidence among Asians and Pacific Islanders in the United States, which would be consistent with the much higher age-adjusted incidence (1.97 per 100,000) reported in an earlier study from Taiwan (12) . In addition, the anatomic distribution of tumor sites [e.g., stomach (55%), small intestines (29%), colon (2.9%), and rectum (2.7%)] was similar to the distribution reported in several earlier studies (2, 4, 12, 13) . Finally, we contributed new evidence to the literature by showing that incidence peaked among patients between 70 and 79 years of age.
The 5-year overall survival rate of 65% was higher than the figure reported by Tran and colleagues in a SEER study between 1992 and 2000, which found a rate of 45% (4). The 5-year GISTspecific survival rate of 79% was also higher than the figure previously reported by DeMatteo and colleagues in a study at Memorial Sloan Kettering between 1982 and 1998, which found a rate of 35% (14), and a single-institution study by Hassan and Figure 1 . Kaplan-Meier survival curves. A, Kaplan-Meier curves for overall and cancerspecific survival after GIST diagnosis. The 5-year overall survival (OS) was 65% (95% CI, 64%-67%), and 5-year GIST-specific survival was 79% (95% CI, 77%-80%). B, Kaplan-Meier curves for OS stratified by disease stage at GIST diagnosis. In the era of tyrosine kinase inhibitor therapy, 3,336 patients with localized GIST had a 5-year OS of 77% (95% CI, 75%-78%), 895 patients with regional disease had a 5-year OS of 64% (95% CI, 60%-67%), and 1,346 patients with distant metastases had a 5-year OS of 41% (95% CI, 38%-44%).
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Cancer Epidemiology, Biomarkers & Preventioncolleagues between 1978 and 2004, which reported a rate of 68% (15) . Although treatment data are not available in the SEER database, the improved survival is likely attributable to the introduction of imatinib in 2000 (1), as 80% to 90% of patients with metastatic disease responded to imatinib, which was highly effective in shrinking or stabilizing tumors with continuous therapy (16) . Like the report by Tran and colleagues (4), we also found black race, older age, and advanced stage to be associated with worse prognoses, which conflicted with prior claims of a lack of survival disparity between black and white patients (6) . In addition, our results supported a Taiwanese study showing male sex to be associated with worse overall survival, but contradicts its claim that tumor location in the small intestine rather than stomach is a significant independent factor correlated with higher mortality (12) . After controlling for other variables such as tumor site and disease stage, we also found that primary tumors larger than 5 cm were not indicative of worse overall survival when compared with primary tumors less than 2 cm.
Results from the multivariate Cox analysis also contradicted previous findings showing tumor size as a significant predictor of GIST-specific survival (14), as we did not find tumors larger than 5 cm to be associated with worse GIST-specific survival than tumors smaller than 2 cm. Unlike Cox analyses conducted previously (15), we also did not find tumors located in the small intestines to be associated with worse GIST-specific survival than tumors located in the stomach. Finally, our results indicated an improvement in GIST-specific survival during the latter years of our study (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) , although this failed to translate into an improvement in overall survival. This finding suggests that the improvement in GIST-specific survival in later years was offset by a concurrent increased risk in non-GIST mortality. As the first epidemiologic study to incorporate histology coding, we were able to more precisely identify GIST patients, and, by extension, GIST epidemiology in the United States. However, because cancers were identified using histology and site-specific codes, misdiagnosis and miscoding were still potential sources of error. Also, because the current ICD-O-3 GIST histology code was instated in 2001, we likely underestimated the actual number of patients with GIST in SEER, particularly at the beginning of our study period. This might explain, in part, the 42% increase in incidence between 2001 and 2011, which was likely due to the increased application of GIST histology codes over time.
In summary, older population-based reports on GIST epidemiology suffer from misdiagnoses and miscoding, which could bias results and skew analyses. The advent of a GIST-specific histology code in the early 2000s allowed us to more accurately identify GIST and describe its epidemiology, which may carry important diagnostic, prognostic, and therapeutic implications.
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